Scarica l'app Stockscreener
0.187
2.19%
0.004
Dopo l'orario di chiusura:
.19
0.003
+1.60%
Precedente Chiudi:
$0.183
Aprire:
$0.1859
Volume 24 ore:
239.17K
Relative Volume:
0.05
Capitalizzazione di mercato:
$4.00M
Reddito:
-
Utile/perdita netta:
$-20.26M
Rapporto P/E:
-0.0219
EPS:
-8.54
Flusso di cassa netto:
$-8.25M
1 W Prestazione:
+0.38%
1M Prestazione:
-28.08%
6M Prestazione:
-45.16%
1 anno Prestazione:
-82.36%
Intervallo 1D:
$0.1805
$0.192
Intervallo di 1 settimana:
$0.17
$0.192
Portata 52W:
$0.1617
$3.43
Oragenics Inc Stock (OGEN) Company Profile
Nome
Oragenics Inc
Settore
Industria
Telefono
813-286-7900
Indirizzo
4902 Eisenhower Boulevard, Suite 125, Tampa, FL
Confronta OGEN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
OGEN
Oragenics Inc
|
0.187 | 4.00M | 0 | -20.26M | -8.25M | -8.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
490.47 | 128.67B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
585.49 | 60.99B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
599.87 | 36.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
236.75 | 29.89B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
252.77 | 25.74B | 3.81B | -644.79M | -669.77M | -6.24 |
Oragenics Inc Borsa (OGEN) Ultime notizie
Oragenics (NYSE:OGEN) Now Covered by Analysts at StockNews.com - Defense World
Oragenics, Inc. Announces Health and Disability Ethics Committee - GuruFocus
Oragenics, Inc. Announces Health and Disability Ethics Committee Submission for Phase IIa Concussion Trial - The Manila Times
Oragenics Announces Health And Disability Ethics Committee Submission - MarketScreener
Oragenics, Inc. Participates in the 3rd Nasal Formulation & Delivery Summit - GlobeNewswire
Oragenics gears up for Phase II trials, appoints new CEO - MSN
Oragenics (NYSE:OGEN) Coverage Initiated at StockNews.com - Defense World
OGEN stock touches 52-week low at $0.19 amid sharp annual decline By Investing.com - Investing.com South Africa
OGEN stock touches 52-week low at $0.19 amid sharp annual decline - Investing.com
Oragenics (NYSE:OGEN) Now Covered by StockNews.com - Defense World
Oragenics reports progress in concussion drug development By Investing.com - Investing.com South Africa
OGEN stock touches 52-week low at $0.24 amid sharp annual decline By Investing.com - Investing.com South Africa
OGEN stock touches 52-week low at $0.24 amid sharp annual decline - Investing.com
Oragenics reports progress in concussion drug development - Investing.com
Oragenics Provides Q1 2025 Shareholder Update On Strategic And Financial Progress - MarketScreener
Oragenics, Inc. Provides Q1 2025 Shareholder Update on Strategic and Financial Progress - The Manila Times
Oragenics (NYSE:OGEN) Coverage Initiated by Analysts at StockNews.com - Defense World
Investornewsbreaks Oragenics Inc. Files 2024 Annual Report, Addresses Going Concern Status - MENAFN.COM
CEMATRIX To Report Fourth Quarter and 2024 Year End Results on March 26, 2025 - The Manila Times
Oragenics, Inc. Announces Filing of 2024 Annual Report on Form 10-K - TradingView
Oragenics, Inc. Files Annual Report for 2024, Receives Unqualified Audit Opinion - Nasdaq
Going Concern Alert: Oragenics Brain Treatment Pipeline Faces Critical Financial Test - StockTitan
OGEN Stock Plummets to 52-Week Low of $0.25 Amid Market Struggles - Investing.com Australia
OGEN Stock Plummets to 52-Week Low of $0.25 Amid Market Struggles By Investing.com - Investing.com South Africa
Oragenics Inc. (OGEN) reports earnings - qz.com
StockNews.com Begins Coverage on Oragenics (NYSE:OGEN) - Defense World
The Oragenics Inc (OGEN) Stock Is Headed for a Correction - US Post News
Digital Risk Inc. Launches Digital Footprint Exposure Assessment Tool to Combat Human Cybersecurity Risks - The Manila Times
Oragenics, Inc. Submits Investigator's Brochure for Phase II Clinical Trial of ONP-002 in Australia for Mild Traumatic Brain Injury - Nasdaq
Oragenics, Inc. Submits Investigator’s Brochure for Phase - GlobeNewswire
Oragenics, Inc. Submits Investigator’s Brochure for Phase II Clinical Trial of ONP-002 in Mild Traumatic Brain Injury (mTBI) - Yahoo Finance UK
Oragenics, Inc. Chief Medical Officer, Dr. James P. Kelly, to Present at the Emergencies in Medicine Conference on Advancing Concussion Treatment - The Manila Times
Heritage Distilling Co. Cocoa Bomb Chocolate Whiskey Named 'Best Flavored Whiskey” in the United States at Whisky Magazine's World Whiskies Awards - The Manila Times
Oragenics, Inc. to Present Concussion Treatment Advancements at Emergencies in Medicine Conference - Nasdaq
Oragenics, Inc. Chief Medical Officer, Dr. James P. Kelly, - GlobeNewswire
Oragenics, Inc. Chief Medical Officer, Dr. James Kelly, Joins the Medical Board of The Leigh Steinberg Foundation for Concussion, Traumatic Brain Injury, and Brain Health - The Manila Times
CytoDyn Announces Promising Survival Observations in mTNBC Patients Treated with Leronlimab - The Manila Times
Oragenics, Inc. Chief Medical Officer, Dr. James Kelly, - GlobeNewswire
5 Top AI Stocks I'm Buying on the Dip - The Globe and Mail
StockNews.com Initiates Coverage on Oragenics (NYSE:OGEN) - Armenian Reporter
Oragenics, Inc. Announces Partnership with BRAINBox - GlobeNewswire
Oragenics Partners With BRAINBox To Develop Intranasal Therapy For Concussion Treatment - Nasdaq
Oragenics Inc Azioni (OGEN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.00%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):